Vaxcyte Total Cash From Financing Activities from 2010 to 2024

PCVX Stock  USD 91.70  3.16  3.57%   
Vaxcyte Total Cash From Financing Activities yearly trend continues to be fairly stable with very little volatility. Total Cash From Financing Activities is likely to outpace its year average in 2024. During the period from 2010 to 2024, Vaxcyte Total Cash From Financing Activities regression line of annual values had r-squared of  0.56 and arithmetic mean of  177,995,835. View All Fundamentals
 
Total Cash From Financing Activities  
First Reported
2019-03-31
Previous Quarter
110.4 M
Current Value
1.5 B
Quarterly Volatility
367.9 M
 
Covid
Check Vaxcyte financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vaxcyte's main balance sheet or income statement drivers, such as Interest Income of 66.1 M, Interest Expense of 0.0 or Selling General Administrative of 63.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 5.16. Vaxcyte financial statements analysis is a perfect complement when working with Vaxcyte Valuation or Volatility modules.
  
Check out the analysis of Vaxcyte Correlation against competitors.
For more information on how to buy Vaxcyte Stock please use our How to Invest in Vaxcyte guide.

Latest Vaxcyte's Total Cash From Financing Activities Growth Pattern

Below is the plot of the Total Cash From Financing Activities of Vaxcyte over the last few years. It is Vaxcyte's Total Cash From Financing Activities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vaxcyte's overall financial position and show how it may be relating to other accounts over time.
Total Cash From Financing Activities10 Years Trend
Slightly volatile
   Total Cash From Financing Activities   
       Timeline  

Vaxcyte Total Cash From Financing Activities Regression Statistics

Arithmetic Mean177,995,835
Geometric Mean2,135,245
Coefficient Of Variation169.49
Mean Deviation244,806,708
Median43,859
Standard Deviation301,679,340
Sample Variance91010.4T
Range861.5M
R-Value0.75
Mean Square Error42700.4T
R-Squared0.56
Significance0
Slope50,675,459
Total Sum of Squares1274145.9T

Vaxcyte Total Cash From Financing Activities History

2024671.8 M
2023639.8 M
2022861.5 M
202117.8 M
2020374.9 M
201941.6 M
201862.2 M

About Vaxcyte Financial Statements

Vaxcyte investors use historical fundamental indicators, such as Vaxcyte's Total Cash From Financing Activities, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Vaxcyte. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Cash From Financing Activities639.8 M671.8 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Vaxcyte Stock Analysis

When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.